CV Therapeutics, Inc. (CVTX) is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CVT currently has several potential growth drivers.
The company received some very positive news on November 5, 2008 when the FDA approved the company's key drug, Ranexa, for use in the first-line indication for chronic angina. The new expanded label removed previous cautionary language limiting use with other cardiovascular medications, and now allows management to promote the drug with added claims on arrhythmias, atrial fibrillation, and a reduction in hemoglobin A1c. Ranexa prescriptions grew nicely in the third quarter 2008, and all systems are go for significantly improved sales in 2009 thanks to the newly expanded label.
We are encouraged by the strong fundamentals at CVT and believe the shares are looking attractive at prices below $8.
Read the full analyst report on CVTX
Get real-time market insights and profitable stock recommendations from the team of analysts at Zacks Equity Research. See all todays Analyst Blog entries on Zacks.com.